Sector Update : Pharmaceuticals - US products prescription trends By Elara Capital
US products prescription trends
We recently analyzed the prescription market share trends of India’s pharmaceuticals firms in key US products. Key takeaways are as follows:
Sun Pharma’s specialty continues to shine
Ilumya and Cequa continue to showcase strong ramp-up in prescription. Cequa has reached above 7% market share in the Cyclosporine market despite generic competition in Restasis. Winlevi, however, has been flat in the past two quarters.
Revlimid market share trends
Dr. Reddy’s Labs volume has started to pick up while Cipla’s has settled. SUNP was launched in April 2023 and continues to ramp up. Zydus’ volume is lumpy with most sales occurring in the first half of the calendar year. ARBP was launched in November 2023.
Cipla’s Albuterol market share on the decline
Cipla continues to ramp up its market share in Lanreotide. The company has retained its market share in Pregabalin but continues to lose market share in Albuterol with a share of 12%.
Zydus Lifesciences gChantix ramp-up continues
Zydus Lifesciences launched gChantix during Q2FY24. The company has gained a 9% market share. Incremental competition is entering gChantix with GNP launch in Q3FY24. Asacol HD has been on a decline while Zydus continues to gain market share in gLialda. In Glumetza, Zydus and Aurobindo Pharma have lost market share to Granules India and Laurus Labs.
Lupin posts strong gSpiriva volume; Albuterol share at 18%
gSpiriva has gained 20%+ market share after Lupin launched it in Q2FY24. It has done well with Albuterol, snatching Cipla’s share with current market share at 18% in the overall Albuterol inhaler market.
Dr. Reddy’s Labs market share ramp-up in Suboxone
DRRD continues to gain market share in the Suboxone market with a share at 27% in November 2023. While it has retained a strong market share in Valsartan at 14% and gVascepa at 17%. DRRD has lost market share in gTecfidera in recent weeks. We retain our rating, TP and estimates for the companies under our coverage.
Above views are of the author and not of the website kindly read disclaimer
